Noetik Secures $40 Million Series A Financing to Advance Precision Cancer Therapies

Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer ther­a­peu­tics, announced today that it closed an over­sub­scribed $40 million Series A financing round.

The financing was led by Polaris Partners and managing partner Amy Schulman, who will join the board of directors, with partic­i­pa­tion from new investors Khosla Ventures, Wittington Ventures and Breakout Ventures. The round was supported by all existing investors DCVC, Zetta Venture Partners, Catalio Capital Management, 11.2 Capital, Epic Ventures, Inter­moun­tain Ventures and North South Ventures. The round also included AI funds ApSTAT Tech­nolo­gies, Linearis Labs and Ventures Fund, supported by leading AI expert Yoshua Bengio and metabolomic expert David Wishart, Element AI co-founder Jean-Francois Gagne, and current and former Recursion executives.

Funds from the Series A financing will be used to expand Noetik’s spatial omics-based atlas of human cancer biology (already one of the world’s largest) together with its high throughput in vivo CRISPR Perturb-Map platform. Addi­tion­ally, the investment will enable the company to scale training of its multi-modal cancer foundation models such as OCTO. The company will leverage these platform capa­bil­i­ties to advance an innovative pipeline of cancer ther­a­peu­tics candidates to the clinic.

“We are thrilled to have the support of incredible investors who share our vision of combining deep patient data and artificial intel­li­gence to build the future of cancer ther­a­peu­tics. This significant financing will enable us to accelerate our progress toward turning biological insights into a portfolio of therapeutic candidates” said Ron Alfa, M.D., Ph.D., CEO & Co-Founder, Noetik.

Noetik was founded to solve critically important challenges in bringing effective new ther­a­peu­tics to patients: improving target discovery and biomarker development to increase the probability of clinical success. To address these, the company has built a discovery and development platform that pairs human multimodal spatial omics data purpose-built for machine learning with a massively multiplexed in vivo CRISPR pertur­ba­tion platform (Perturb-Map). Together these data are used to train self-supervised foundation models of tissue and tumor biology that power the company’s discovery efforts.

“We are excited to partner with Noetik and support their mission to build a pipeline of potentially trans­for­ma­tive cancer programs,” said Amy Schulman, Managing Partner, Polaris Partners. ​“We have been investing in the most innovative life science tech­nolo­gies for decades and have been excited about the potential of AI. Noetik impressed us both with the sophis­ti­ca­tion of their platform and the team’s dedication to make an impact for patients.”

The company aims to establish strategic part­ner­ships and collab­o­ra­tions with leading academic insti­tu­tions, health care providers, and phar­ma­ceu­tical companies. The company recently appointed Shafique Virani, M.D. as the company’s Chief Business Officer to spearhead these partnering efforts.

“We are thrilled to continue backing Noetik. The team’s speed of execution in building one of the most sophis­ti­cated AI-enabled oncology discovery engines in less than two years is unprece­dented, and their deep experience and demon­strable progress have only strength­ened our conviction,” said James Hardiman, General Partner, DCVC.

Noetik is committed to advancing the field of precision oncology and improving outcomes for cancer patients worldwide. This Series A funding marks a significant milestone in the company’s journey and reinforces its position as a leader in the development of AI-driven cancer therapies.

To learn more about our compre­hen­sive patient dataset, visit https://www.noetik.ai/lungcanceratlas

About Noetik

Noetik is an AI-native biotech­nology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision therapies. The company is based in San Francisco, CA. For more information, visit https://www.noetik.ai/.